National Bank of Canada FI Has $5.12 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

National Bank of Canada FI raised its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 42.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,987 shares of the medical research company's stock after purchasing an additional 10,132 shares during the quarter. National Bank of Canada FI owned 0.07% of Charles River Laboratories International worth $5,116,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Rothschild Investment LLC increased its holdings in Charles River Laboratories International by 480.0% during the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after purchasing an additional 144 shares during the last quarter. HM Payson & Co. acquired a new position in Charles River Laboratories International during the 1st quarter valued at approximately $31,000. Optiver Holding B.V. acquired a new position in Charles River Laboratories International during the 4th quarter valued at approximately $37,000. GeoWealth Management LLC raised its stake in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after acquiring an additional 190 shares in the last quarter. Finally, Parallel Advisors LLC raised its stake in Charles River Laboratories International by 83.7% during the 1st quarter. Parallel Advisors LLC now owns 474 shares of the medical research company's stock valued at $71,000 after acquiring an additional 216 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 400 shares of Charles River Laboratories International stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $150.04, for a total transaction of $60,016.00. Following the transaction, the executive vice president directly owned 24,916 shares in the company, valued at approximately $3,738,396.64. The trade was a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Wall Street Zen downgraded Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research note on Sunday. JPMorgan Chase & Co. boosted their target price on Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Citigroup raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $150.00 to $200.00 in a research report on Wednesday, July 9th. Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their price target for the company from $188.00 to $182.00 in a report on Friday, May 23rd. Finally, Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and a consensus target price of $175.69.

Charles River Laboratories International Trading Up 0.6%

Shares of CRL stock traded up $0.86 during trading hours on Friday, reaching $156.66. The company had a trading volume of 1,038,291 shares, compared to its average volume of 1,079,568. The company has a 50 day moving average of $156.87 and a 200 day moving average of $148.86. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The firm has a market cap of $7.71 billion, a price-to-earnings ratio of -117.79, a P/E/G ratio of 5.00 and a beta of 1.48. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.62. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%. The company's revenue for the quarter was up .6% on a year-over-year basis. During the same period in the previous year, the company posted $2.80 earnings per share. On average, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).